Table IV.
Group | n | a-SMA | CXCR4 | ERK1 | ERK2 | NF-κB p65 | β-catenin |
---|---|---|---|---|---|---|---|
Model week 4 | 10 | 8.998±0.267 | 1.424±0.186 | 1.133±0.050 | 1.104±0.046 | 4.338±0.176 | 2.433±0.324 |
YGD week 1 | 10 | 7.107±0.429a | 1.441±0.302 | 1.369±0.081a | 1.291±0.039a | 3.475±0.369a | 2.080±0.147a |
YGD week 2 | 10 | 5.016±0.333a,b | 2.903±0.350a,b | 1.620±0.026a,b | 1.505±0.021a,b | 1.837±0.175a,b | 1.699±0.083a,b |
YGD week 3 | 10 | 3.269±0.267a,c | 4.236±0.510a,c | 1.835±0.090a,c | 2.123±0.082a,c | 1.309±0.053a,c | 1.237±0.539a,c |
YGD week 4 | 14 | 1.883±0.311a,d | 5.925±1.067a,d | 2.408±0.151a,d | 2.831±0.256a,d | 1.147±0.115a,d | 1.088±0.012a,d |
Data are presented as the mean ± standard deviation.
P<0.05 vs. model week 4
P<0.05 vs. YGD week 1
P<0.05 vs. YGD week 2
P<0.05 vs. YGD week 3. YGD, Yi Guan Jian decoction; α-SMA, α-smooth muscle actin; CXCR4, C-X-C chemokine receptor type 4; ERK1/2, extracellular signal-regulated kinase 1/2; NF-κB p65, nuclear factor κB p65 subunit.